These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21769839)

  • 1. Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests.
    Schreiber BE; Valerio CJ; Keir GJ; Handler C; Wells AU; Denton CP; Coghlan JG
    Arthritis Rheum; 2011 Nov; 63(11):3531-9. PubMed ID: 21769839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization.
    Hsu VM; Moreyra AE; Wilson AC; Shinnar M; Shindler DM; Wilson JE; Desai A; Seibold JR
    J Rheumatol; 2008 Mar; 35(3):458-65. PubMed ID: 18203320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of echocardiography and pulmonary function tests could predict no complication of pulmonary hypertension during 5 years in patients with systemic sclerosis.
    Yoneda K; Takahashi S; Nakayama K; Iwahashi M; Emoto N; Kumagai S
    Int J Rheum Dis; 2023 Mar; 26(3):493-500. PubMed ID: 36737419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment.
    Proudman SM; Stevens WM; Sahhar J; Celermajer D
    Intern Med J; 2007 Jul; 37(7):485-94. PubMed ID: 17547726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis.
    Ninagawa K; Kato M; Nakamura H; Abe N; Kono M; Fujieda Y; Oku K; Yasuda S; Ohira H; Tsujino I; Atsumi T
    Rheumatol Int; 2019 Nov; 39(11):1883-1887. PubMed ID: 31280357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France.
    Hachulla E; de Groote P; Gressin V; Sibilia J; Diot E; Carpentier P; Mouthon L; Hatron PY; Jego P; Allanore Y; Tiev KP; Agard C; Cosnes A; Cirstea D; Constans J; Farge D; Viallard JF; Harle JR; Patat F; Imbert B; Kahan A; Cabane J; Clerson P; Guillevin L; Humbert M;
    Arthritis Rheum; 2009 Jun; 60(6):1831-9. PubMed ID: 19479881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.
    Valerio CJ; Schreiber BE; Handler CE; Denton CP; Coghlan JG
    Arthritis Rheum; 2013 Apr; 65(4):1074-84. PubMed ID: 23280155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry.
    Bae S; Saggar R; Bolster MB; Chung L; Csuka ME; Derk C; Domsic R; Fischer A; Frech T; Goldberg A; Hinchcliff M; Hsu V; Hummers L; Schiopu E; Mayes MD; McLaughlin V; Molitor J; Naz N; Furst DE; Maranian P; Steen V; Khanna D
    Ann Rheum Dis; 2012 Aug; 71(8):1335-42. PubMed ID: 22307943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis.
    Coghlan JG; Wolf M; Distler O; Denton CP; Doelberg M; Harutyunova S; Marra AM; Benjamin N; Fischer C; Grünig E
    Eur Respir J; 2018 Apr; 51(4):. PubMed ID: 29563168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
    Garin MC; Highland KB; Silver RM; Strange C
    J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
    Launay D; Mouthon L; Hachulla E; Pagnoux C; de Groote P; Remy-Jardin M; Matran R; Lambert M; Queyrel V; Morell-Dubois S; Guillevin L; Hatron PY
    J Rheumatol; 2007 May; 34(5):1005-11. PubMed ID: 17444586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of exercise pulmonary arterial hypertension in scleroderma.
    Callejas-Rubio JL; Moreno-Escobar E; de la Fuente PM; Pérez LL; Fernández RR; Sánchez-Cano D; Mora JP; Ortego-Centeno N
    J Rheumatol; 2008 Sep; 35(9):1812-6. PubMed ID: 18634147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ventricular mass index correlates with pulmonary artery pressure and predicts survival in suspected systemic sclerosis-associated pulmonary arterial hypertension.
    Hagger D; Condliffe R; Woodhouse N; Elliot CA; Armstrong IJ; Davies C; Hill C; Akil M; Wild JM; Kiely DG
    Rheumatology (Oxford); 2009 Sep; 48(9):1137-42. PubMed ID: 19605369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease.
    Andersen KH; Iversen M; Kjaergaard J; Mortensen J; Nielsen-Kudsk JE; Bendstrup E; Videbaek R; Carlsen J
    J Heart Lung Transplant; 2012 Apr; 31(4):373-80. PubMed ID: 22226804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations.
    Meune C; Avouac J; Airò P; Beretta L; Dieudé P; Wahbi K; Caramaschi P; Tiev K; Cappelli S; Diot E; Vacca A; Cracowski JL; Sibilia J; Kahan A; Matucci-Cerinic M; Allanore Y
    Arthritis Rheum; 2011 Sep; 63(9):2790-6. PubMed ID: 21547892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary hypertension in chronic lung diseases.
    Seeger W; Adir Y; Barberà JA; Champion H; Coghlan JG; Cottin V; De Marco T; Galiè N; Ghio S; Gibbs S; Martinez FJ; Semigran MJ; Simonneau G; Wells AU; Vachiéry JL
    J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D109-16. PubMed ID: 24355635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population.
    Hinchcliff M; Fischer A; Schiopu E; Steen VD;
    J Rheumatol; 2011 Oct; 38(10):2172-9. PubMed ID: 21844142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.
    Steen V; Medsger TA
    Arthritis Rheum; 2003 Feb; 48(2):516-22. PubMed ID: 12571862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
    Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
    Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study.
    Hsu VM; Chung L; Hummers LK; Wigley F; Simms R; Bolster M; Silver R; Fischer A; Hinchcliff ME; Varga J; Goldberg AZ; Derk CT; Schiopu E; Khanna D; Shapiro LS; Domsic RT; Medsger T; Mayes MD; Furst D; Csuka ME; Molitor JA; Alkassab F; Steen VD
    Semin Arthritis Rheum; 2014 Aug; 44(1):55-62. PubMed ID: 24709277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.